SAN JOSE, Calif., September 6, 2016 — Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (“Luoxin”) to market, sell, and distribute TPU’s Docetaxel Injection, Non-Alcohol Formula in China. Docetaxel Injection Non-Alcohol Formula received U.S. Food and Drug Administration (“FDA”) approval on December 22th 2015. Under the terms of the agreement, Luoxin will pay Teikoku near-term milestones, royalties on net sales after commercial launch.
“We are very excited to license our Docetaxel Injection to Luoxin, an established leader in specialty injectables in China. We are confident that Luoxin can capture a significant share of the market for this important product,” said Paul Mori, Chief Executive Officer of Teikoku.
“Our mission is to improve the quality of life of patients around the world by providing new benefits for unmet patient needs,” added Mori.
About Docetaxel Injection Docetaxel is a cytotoxic anticancer agent indicated for treating breast cancer, non-small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck cancer.
Teikoku’s Docetaxel Injection comes as one vial docetaxel injection in three presentations: 20mg/1ml, 80mg/4mL, and 160mg/8mL.
About Teikoku Pharma USA
Teikoku Pharma USA Inc., located in San Jose, California is a wholly-owned subsidiary of Teikoku Seiyaku Co., LTD. of Japan, is an international specialty pharmaceutical company that develops and manufactures pharmaceutical products based on its delivery platform technologies.
Teikoku’s main product is Lidoderm® (Lidocaine 5% Patch) for PHN, developed by Teikoku and distributed by Endo Pharmaceuticals in the U.S and Grunenthal GmbH in Europe and Latin America as Versatis®.
Teikoku’s internal therapeutic focus is in Pain Management, CNS and Oncology.
About Luoxin Pharmaceutical
Founded in 1988, Luoxin is a well-established domestic pharmaceutical company in China, which has the full capability of R&D, manufacture, supply, commercialization (total employees 5500 in 2015). In 2014, Luoxin Shanghai R&D center was set up, with the commitment to enrich current pipelines (generics) with innovative medicines, through in-licensing and strategic partnerships. With the comprehensive capabilities in China market, Luoxin is committed and dedicated to provide good medicines to Chinese patients. Luoxin focuses on the therapeutic areas such as cardiovascular diseases, endocrinology, gastroenterology, respiratory diseases and oncology.
For more information please contact: Francisco Bejar at fbejar@teikokuusa.com